More wonders of modern medicine [Zetia]

[Guest guest]

Ralph W. Moss, Ph.D. Weekly CancerDecisions.com

Newsletter #325 01/27/08

 

THE MOSS REPORTS - CANCER DECISIONS NEWSLETTER

 

ZETIA FAILS CLINICAL TRIAL…WHY WAS IT EVER APPROVED?

 

This month, scientists announced the result of the long-awaited ENHANCE

study of the anti-cholesterol drug Zetia (ezetimibe). This drug alone,

or in combination with the popular statin drug, Zocor (simvastatin)

conveyed no medical benefit to patients. In fact, the company-sponsored

study found that the pace at which artery-clogging plaque formed within

blood vessels actually doubled in patients taking the two-drug

combination.

 

To read or listen to this week's newsletter, please click here or go to:

http://www.cancerdecisions.com/012708.html

[and scroll down]

 

To SUBSCRIBE TO OUR FREE NEWSLETTER: Please go to

http://cancerdecisions.com/list/optin.php?form_id=8

and follow the instructions to be automatically added to this list.

Thank you.

CancerDecisions®

PO Box 1076, Lemont, PA 16851

Phone Toll Free: 800-980-1234 | Fax: 814-238-5865

1996-2007